Signals suggest the drugs could improve on the standard of care, but the market may not make it easy for another megablockbuster to rise to the top.

In the last reported quarter, U.S. sales of Keytruda were negatively impacted by around $250 million due to the timing of ...

Many pharmaceutical products made in Europe will face a 15 percent tariff, pinching manufacturers and potentially leading to ...

Merck is heading into its second-quarter earnings report on Tuesday with important pillars of its business increasingly under ...

European pharma companies are breathing a sigh of relief after the Trump administration posed a 15% tariff, rather than 200% ...

Merck has had a successful track record of beating estimates, having surpassed EPS expectations 88% of the time and beating ...

Thankfully, some income stocks on the market don't have these issues, and their shares are worth holding on to forever. Let's ...

IO Biotech’s off-the-shelf cancer vaccine shows promise in melanoma with key data ahead, but funding risk limits near-term ...

Months have passed since Mary Barnes had a double mastectomy to treat an “aggressive” form of breast cancer. Now her treatments have been put on hold because of insurance denials.

Data from the KEYNOTE-B61 trial show tumor shrinkage in different types of kidney cancer, including papillary and chromophobe ...

With Virgin shares holding nicely at cruising altitude, is now the right time for private oncology drug developer Qbiotics to ...

Three Motley Fool contributors have picked surprisingly underrated stocks to buy right now. Here's why they chose big pharma ...